Geistlich Pharma AG, a Swiss manufacturer of medical products today announced the commencement of its Indian operations, by establishing Geistlich Pharma India Pvt Ltd, a wholly owned subsidiary and the 10th global affiliate. With this announcement, the two globally patented products Bio-Oss and Bio-Gide used for dental regeneration around the world will now be available across India.
Geistlich Pharma AG uses its patented technology for providing dental regeneration biomaterials in over 90 countries today. Geistlich Bio-Oss and Geistlich Bio-Gide are considered gold standards of the Regenerative materials as they are the most studied and researched biomaterials across the globe. The strength and the quality of these brands are demonstrated with an estimate that a Geistlich Biomaterial is used every 18 seconds. 2016 has a special importance for Geistlich as Bio-Oss has completed 30 years and Bio-Gide has completed 20 years of clinical use and the biomaterials range has achieved a milestone of 1000 clinical studies worldwide”.
Present on the launch in New Delhi, Mr. Paul Note, CEO of Geistlich Pharma AG said, “We are very pleased to enter this dynamic & promising Indian market that has been showing a paradigm shift in its healthcare delivery mechanism. We are here not only at an opportune time, but I genuinely feel that Indian medical eco system is maturing and is increasingly receptive to best in class medical care. Our products supplement the patient’s complete dentistry-care requirements. In addition, we view India as a strategic fit for our business growth worldwide.”
Geistlich Bio-Oss and Geistlich Bio-Gide have earned the reputation of a trusted technology among leading healthcare service providers in the world. The two products function as a clinical solution for bone regeneration and oral tissue regeneration, respectively. Their wide application in dentistry can be understood by the fact, that they help patients suffering from problems in the oral cavity; whether the patient undergoes tooth extraction or tissue preservation. In case of dental implants, the complete dental anatomy can be strengthened, which includes a patient’s bone and soft tissue.
Mr. Sandeep Ghavri, General Manager of Geistlich India, commented “we see Geistlich Pharma India as a new process beginning in the Indian healthcare service industry. It is not just about being able to access a range of products with proven track record especially Bio-Oss and Bio-Gide, but also to leverage Geistlich’s vast experience and research of over 30 years in dental regeneration and 150 years of expertise handling natural tissues and bone. This is a new chapter in Indian dentistry, where the Indian people will now be aware of regenerative bio-material and the benefits they offer.”
About Geistlich Pharma AG
Geistlich Pharma AG develops, manufactures and markets medical products for restoring bone, cartilage and soft tissues as well as drugs. The Swiss company encompasses three business Units: Geistlich Biomaterials, Geistlich Surgery and Geistlich Medical and operates from Wolhusen and Root sites near Lucerne, Switzerland. Geistlich Pharma is part of the Geistlich Group and has been family owned since 1851.Geistlich Pharma has a worldwide sales and distribution network with 10 affiliates and operations in more than 90 countries. The company has been the world market leader in regenerative dentistry for decades.